Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Risa Kagan, James A Simon, Steven R Goldstein, Barry S Komm, Simon N Jenkins, David J Portman
OBJECTIVE: The aim of this study was to demonstrate whether lasofoxifene improves vaginal signs/symptoms of genitourinary syndrome of menopause. METHODS: Two identical, phase 3 trials randomized postmenopausal women with moderate to severe vaginal symptoms to oral lasofoxifene 0.25 or 0.5 mg/d, or placebo, for 12 week. Changes from baseline to week 12 in most bothersome symptom, vaginal pH, and percentages of vaginal parabasal and superficial cells were evaluated...
April 23, 2024: Menopause: the Journal of the North American Menopause Society
#2
JOURNAL ARTICLE
Jacques Donnez, Christian Becker, Hugh Taylor, Francisco Carmona Herrera, Olivier Donnez, Andrew Horne, Maciej Paszkowski, Felice Petraglia, Stefan P Renner, Amisha Patel, Mitra Boolell, Elke Bestel, Marie-Madeleine Dolmans
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demonstrate better efficacy than placebo in the management of endometriosis-related dysmenorrhea and non-menstrual pelvic pain? SUMMARY ANSWER: Combining 200 mg linzagolix with ABT was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain at 3 months of therapy, while a daily dose of 75 mg linzagolix yielded a significant decrease only in dysmenorrhea at 3 months...
April 22, 2024: Human Reproduction
#3
JOURNAL ARTICLE
Ahmed A Abo Elnaga, Mohamed A Alsaied, Abdelrahman M Elettreby, Alaa Ramadan
BACKGROUND & OBJECTIVE: Vasomotor symptoms (VMS) are the most common symptoms during menopause including hot flushes and night sweats. They are highly disruptive to the quality of life. Fezolinetant is an FDA-approved non-hormonal selective neurokinin3 receptor antagonist for the treatment of VMS. In this study, we aim to assess the efficacy and safety of fezolinetant for VMS associated with menopause. METHODS: Databases were searched until September 2023 for relevant studies comparing fezolinetant against placebo...
April 15, 2024: European Journal of Obstetrics, Gynecology, and Reproductive Biology
#4
JOURNAL ARTICLE
Susu Zhou, Parissa Alerasool, Noriko Kishi, Himanshu Joshi, Gagan Sahni, Che-Kai Tsao
INTRODUCTION: Second-generation androgen receptor axis-targeting (ARAT) agents have become a standard treatment for patients with advanced prostate cancer (PC), however much remains unknown about the potential cardiovascular toxicities. PATIENTS AND METHODS: We performed a systematic search of PubMed, Embase, Web of Science, and Cochrane library for randomized controlled trials of patients receiving ARAT agents for PC from inception to March 2023. The odds ratios (ORs) of all-grade and high-grade cardiovascular adverse events (CVAEs) for patients treated with and without ARAT agents were pooled for meta-analysis...
March 8, 2024: Clinical Genitourinary Cancer
#5
REVIEW
Panagiotis Anagnostis, Konstantinos Lallas, Anna Pappa, Georgios Avgeris, Kristina Beta, Dimitrios Damakis, Eirini Fountoukidou, Maria Zidrou, Irene Lambrinoudaki, Dimitrios G Goulis
BACKGROUND/AIMS: Vasomotor symptoms (VMS) adversely affect postmenopausal quality of life. However, their association with bone health has not been elucidated. This study aimed to systematically review and meta-analyze the evidence regarding the association of VMS with fracture risk and bone mineral density (BMD) in peri- and postmenopausal women. METHODS: A literature search was conducted in PubMed, Scopus and Cochrane databases until 31 August 2023. Fracture, low BMD (osteoporosis/osteopenia) and mean change in lumbar spine (LS) and femoral neck (FN) BMD were assessed...
April 2, 2024: Osteoporosis International
#6
S Ramyashree, Jacintha Veigas, Deepa Kanagal
BACKGROUND: Menopause is experienced by every woman; some women attain it very early as they reach 42 years old. This happens when there is a dysfunction of follicles. The symptoms experienced by the women vary from mild to severe. The study aims to identify the severity of menopausal symptoms and their effect on the quality of life (QOL) among working women. MATERIALS AND METHODS: A cross-sectional research design was used for the study. A total of 93 menopausal working women were selected by using the nonprobability sampling technique...
2024: Journal of Education and Health Promotion
#7
JOURNAL ARTICLE
Madeline Günther, Peter Schnierle, Thorsten Rose, Jonathan Schlegel, Georg Boonen, Jürgen Drewe, Eduardo Muñoz, Bernd L Fiebich, Carsten Culmsee
Cimicifuga racemosa extracts (CREs) have gained well-established use for the treatment of menopausal symptoms such as hot flushes and excessive sweating, and weight gain. While the clinical effects of CREs have been well documented, the mechanisms underlying these effects are largely unknown. More recently, the metabolic effects of the CRE Ze 450 were demonstrated in cultured cells in vitro and in mouse models of obesity in vivo. At the molecular level, metabolic regulation, enhanced insulin sensitivity, and increased glucose uptake were linked to the activation of AMP-activated protein kinase (AMPK)...
March 13, 2024: Pharmaceutics
#8
JOURNAL ARTICLE
Andreea Balan, Marius Alexandru Moga, Andrea Elena Neculau, Maria Mitrica, Liliana Rogozea, Petru Ifteni, Lorena Dima
BACKGROUND: The objective of this study was to determine the effects of royal jelly and fermented soy extracts on menopausal symptoms and on quality of life in pre- and post-menopausal women. MATERIALS AND METHOD: This prospective observational study was carried out in a Clinical Hospital of Brasov, Romania, during June 2020 and December 2021. Eighty pre- and post-menopausal women, aged between 45 and 60 years, were included in two groups. The first group (40 women) received a dietary supplement with fermented soy extract twice a day for eight weeks and the second group (40 women) received the same dietary supplement with fermented soy extracts and 1500 mg of royal jelly capsules for eight weeks...
February 26, 2024: Nutrients
#9
REVIEW
Martha Hickey, Partha Basu, Jenifer Sassarini, Mariken E Stegmann, Elisabete Weiderpass, Karen Nakawala Chilowa, Cheng-Har Yip, Ann H Partridge, Donal J Brennan
Globally, 9 million women are diagnosed with cancer each year. Breast cancer is the most commonly diagnosed cancer worldwide, followed by colorectal cancer in high-income countries and cervical cancer in low-income countries. Survival from cancer is improving and more women are experiencing long-term effects of cancer treatment, such as premature ovarian insufficiency or early menopause. Managing menopausal symptoms after cancer can be challenging, and more severe than at natural menopause. Menopausal symptoms can extend beyond hot flushes and night sweats (vasomotor symptoms)...
March 9, 2024: Lancet
#10
JOURNAL ARTICLE
Kossi Clément Trenou, Miceline Mésidor, Caroline Diorio, Aida Eslami, Denis Talbot
INTRODUCTION: Evaluating the benefits and risks of prolonged hormonal treatment with aromatase inhibitors (AIs) for treating hormone-dependent breast cancer. METHODS: A systematic review and meta-analysis was conducted. Studies reporting on randomized clinical trials concerning prolongating hormonal therapy with AIs as compared to a placebo or no prolongation, after an initial five years of hormonal therapy, were eligible. RESULTS: Seven clinical trials were included...
March 6, 2024: Bulletin du Cancer
#11
REVIEW
Kim Pauwaert, An-Sofie Goessaert, Dudley Robinson, Linda Cardozo, Wendy Bower, Patrick Calders, An Mariman, Paul Abrams, Andrea Tubaro, Roger Dmochowski, Jeffrey P Weiss, Francois Hervé, Herman Depypere, Karel Everaert
INTRODUCTION AND HYPOTHESIS: The aim of this review is to discuss the link between menopause and nocturia and to give an overview of the increasing prevalence, risk factors, causative factors, treatment needs and options for nocturia in peri-menopausal women. METHODS: This opinion article is a narrative review based on the expertise and consensus of a variety of key opinion leaders, in combination with an extensive literature review. This literature search included a thorough analysis of potential publications on both the PubMed Database and the Web of Science and was conducted between November 2022 and December 2022...
March 4, 2024: International Urogynecology Journal
#12
JOURNAL ARTICLE
Aslı Tok Özen, Özlem Bulantekin Düzalan, Betül Yalçın
BACKGROUND: The diagnosis of diabetes mellitus adversely impacts the quality of life due to treatment, changes in daily life, functional disability, and emerging complications. Using metaphors to convey perceptions of diseases and life experiences is crucial for understanding healthcare behaviors. OBJECTIVE: This study aimed to explore the metaphorical perceptions of "diabetes" and "being a person with diabetes" within a sample group of individuals with diabetes in Turkey...
2024: Belitung nursing journal
#13
JOURNAL ARTICLE
Emanuela Elisa Sorbara, Maria Antonietta Barbieri, Giulia Russo, Giuseppe Cicala, Edoardo Spina
INTRODUCTION: Anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAbs) have recently been approved for the prevention of migraine, and their safety profile is not fully characterized. OBJECTIVE: The aim of this study was to evaluate the adverse drug reactions (ADRs) of anti-CGRP-mAbs through the analysis of individual case safety reports (ICSRs) collected in the EudraVigilance (EV) database, with a specific focus on cardiovascular (CV) ADRs. METHODS: Data on ICSRs recorded between July 2018 and December 2022 in the EV database, involving one of the anti-CGRP-mAbs for migraine prevention-erenumab (ERE), galcanezumab (GMB), fremanezumab (FMB), and eptinezumab (EPT)-were included in the analysis...
March 2024: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
#14
JOURNAL ARTICLE
Norah P Scally, Lara Armstrong, Daryl Blades, Eimer McGeown, Helen Mathers
Introduction Standard treatment for oestrogen-positive breast cancers involves a minimum of five years of adjuvant endocrine treatment with a significant improvement in survival. However, the side effects of endocrine treatments are often underestimated. We aimed to identify the frequency of side effects, adherence to treatment, and impact on the quality of life of breast cancer survivors. Methods All patients attending holistic needs assessment and health and wellbeing events with a clinical nurse specialist between March and October 2023 were given a menopause symptom proforma and Utian menopausal quality of life scale questionnaire...
January 2024: Curēus
#15
REVIEW
Taylor Witten, Julia Staszkiewicz, Logan Gold, Mallory A Granier, Rachel J Klapper, Gabriel Lavespere, Bradley Dorius, Varsha Allampalli, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye, Giustino Varrassi
An average of 60-80% of all menopausal women experience bothersome vasomotor symptoms (VMSs), such as flushing and sweating, within the first seven years of onset. However, despite increasing prevalence, these hot flashes remain hard to treat and have a negative effect on the quality of life. Though hormone replacement therapy is commonly utilized as a standard treatment for VMSs, this therapy is not recommended for all women. Specifically, the oral form of hormone replacement therapy is associated with several contraindications, including a history of thromboembolic disease, migraine headache with aura, liver failure, heart disease, and hormone-dependent cancers...
January 2024: Curēus
#16
JOURNAL ARTICLE
Carolin C Hack, Nicolai Maass, Bahriye Aktas, Sherko Kümmel, Christoph Thomssen, Christopher Wolf, Hans-Christian Kolberg, Cosima Brucker, Wolfgang Janni, Peter Dall, Andreas Schneeweiss, Frederik Marme, Matthias Ruebner, Anna-Katharin Theuser, Nadine M Hofmann, Sybille Böhm, Katrin Almstedt, Sara Kellner, Paul Gass, Marc W Sütterlin, Hans-Joachim Lück, Sabine Schmatloch, Matthias Kalder, Christoph Uleer, Ingolf Juhasz-Böss, Volker Hanf, Christian Jackisch, Volkmar Müller, Brigitte Rack, Erik Belleville, Diethelm Wallwiener, Achim Rody, Claudia Rauh, Christian M Bayer, Sabrina Uhrig, Chloë Goossens, Hanna Huebner, Sara Y Brucker, Lothar Häberle, Tanja N Fehm, Alexander Hein, Peter A Fasching
INTRODUCTION: Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore, this study analyzed the prognosis and patient characteristics of postmenopausal patients selected for a five-year upfront letrozole therapy...
February 2024: Geburtshilfe und Frauenheilkunde
#17
JOURNAL ARTICLE
Antonio Cano, Rossella E Nappi, Nanette Santoro, Petra Stute, Martin Blogg, Marci L English, Antonia Morga, Ludmila Scrine, Emad Siddiqui, Faith D Ottery
OBJECTIVE: To assess the effect of fezolinetant treatment on health-related quality of life using pooled data from SKYLIGHT 1 and 2 studies. DESIGN: Prespecified pooled analysis. SETTING: USA, Canada, Europe; 2019-2021. POPULATION: 1022 women aged ≥40 to ≤65 years with moderate-to-severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS. METHODS: Women were randomised to 12-week double-blind treatment with once-daily placebo or fezolinetant 30 or 45 mg...
February 6, 2024: BJOG: An International Journal of Obstetrics and Gynaecology
#18
JOURNAL ARTICLE
Albertas Ulys, Feliksas Jankevicus, Mindaugas Jievaltas, Raimundas Venckus, Stasys Auskalnis, Zygimantas Kardelis, Marija Barisiene, Carol M MacLean, Steve van Os, Finn Larsen
BACKGROUND: Teverelix drug product (DP) is a novel injectable gonadotropin-releasing hormone antagonist. METHODS: An adaptive phase 2, open-label, multicenter trial was conducted in patients with advanced prostate cancer to evaluate the efficacy and safety of a combined subcutaneous (SC) and intramuscular (IM) loading dose regimen of teverelix DP of 120 mg SC + 120 mg IM (Group 1; N = 9) or 180 mg SC + 180 mg IM (Group 2; N = 41) administered at a single visit, followed by 6-weekly SC maintenance doses of 120 mg (Group 1) or 180 mg (Group 2), up to Day 168...
February 4, 2024: Prostate
#19
JOURNAL ARTICLE
Bertrand F Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, Fernando López-Campos, Piet Ost, Thierry Andre Roumeguere, Bernardo Herrera-Imbroda, Lionel A D'Hondt, Magali Quivrin, Paolo Gontero, Salvador Villà, Hussein Khaled, Beatrice Fournier, Jammbe Musoro, Joanna Krzystyniak, Yassin Pretzenbacher, Yohann Loriot
BACKGROUND AND OBJECTIVE: Darolutamide is an androgen receptor inhibitor that increases overall survival in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer (PCa). This phase 2 study assessed the efficacy and safety of darolutamide as monotherapy without ADT in patients with eugonadal testosterone levels. METHODS: This was a 24-wk, open-label, randomized study of patients with hormone-sensitive, histologically confirmed PCa requiring gonadotropin-releasing hormone (GnRH); an Eastern Cooperative Oncology Group performance status score of 0/1; and life expectancy >1 yr...
January 24, 2024: European Urology Oncology
#20
JOURNAL ARTICLE
Megan Pound, Heather Massey, Sasha Roseneil, Ruth Williamson, C Mark Harper, Mike Tipton, Jill Shawe, Malika Felton, Joyce C Harper
OBJECTIVE: This study aimed to determine how women felt cold water swimming affected their menstrual and perimenopausal symptoms. STUDY DESIGN: An online survey that asked women who regularly swim in cold water about their experiences. The survey was advertised for 2 months on social media. Questions related to cold water swimming habits and menstrual and perimenopausal symptoms were analysed. MAIN OUTCOME MEASURES: Quantitative and qualitative data including; frequency of menstrual and menopause symptoms, the effect of cold water swimming on these symptoms...
March 2024: Post Reproductive Health
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
